博雅生物(300294.SZ):終止發行股份、可轉債購買羅益生物48.87%股權
格隆匯4月20日丨博雅生物(300294.SZ)公佈,公司於2020年4月20日召開第六屆董事會第三十二次會議,審議通過了《關於終止發行股份、可轉換公司債券購買資產的議案》,公司董事會決定終止發行股份、可轉換公司債券購買無錫羅益(無錫)生物製藥有限公司48.87%股權事項。
2020年4月11日,公司收到中國證券監督管理委員會出具的《關於不予核准博雅生物製藥集團股份有限公司發行股份、可轉換公司債券購買資產申請的決定》(證監許可[2020]550號)。
2020年4月20日,公司召開第六屆董事會第三十二次會議,審議通過了《關於終止發行股份、可轉換公司債券購買資產的議案》,公司董事會決定終止發行股份、可轉換公司債券購買無錫羅益(無錫)生物製藥有限公司48.87%股權事項。
自證監會併購重組委2020年2月18日召開的會議對此次資產重組事項審核未通過以來,公司積極與交易對方就方案調整等事項進行溝通,雙方未能就交易相關重要條款的調整達成一致意見,經公司審慎研究,決定終止此次資產重組事項。
此次終止資產重組事項是經公司審慎研究後的結果,不會對現有的生產經營和財務狀況造成重大不利影響,不會影響公司未來的發展戰略。公司始終圍繞“世界級血液製品企業、中國製藥企業標杆”的發展戰略,仍將立足於血液製品,逐步發展有特色的醫藥產品的發展戰略,促進業務持續快速增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.